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An innovative gynecological HDR brachytherapy applicator system for treatment
delivery and real-time verification
Abstract
The multichannel vaginal cylinder (MVC) applicator employed for gynecological high dose rate (HDR)
brachytherapy increases dose delivery complexity, and thus makes the treatment more prone to errors. A
quality assurance (QA) procedure tracking the source throughout dose delivery can detect dwell position
and time errors in the multiple channels of the applicator.
A new MVC system with integrated real time in vivo treatment delivery QA has been developed based on
diodes embedded on the outer surface of the MVC. It has been pre-calibrated and verified using a nonclinical treatment plan with consecutive test positions and dwell times within each catheter, followed by
the delivery of ten clinical plans of adjuvant vaginal cuff brachytherapy following hysterectomy for
endometrial cancer.
The non-clinical verification showed overall mean dwell position and time discrepancies between the
nominal and measured treatment of −0.2 ± 0.5 mm and −0.1 ± 0.1 s (k = 1), respectively. The clinical plans
showed mean positional discrepancies of 0.2 ± 0.4 and 0.0 ± 0.8 mm, for the central and peripheral
catheters, respectively, and mean dwell time discrepancies of −0.1 ± 0.2 and −0.0 ± 0.1 s for central and
peripheral catheters, respectively.
The innovative prototype of the MVC system has shown the ability to track the source with sub-mm and
sub-second accuracy, and demonstrated potential for its incorporation into the clinical routine.
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Abstract
The multichannel vaginal cylinder (MVC) applicator employed for gynecological high dose rate
(HDR) brachytherapy increases dose delivery complexity, and thus makes the treatment more
prone to errors. A quality assurance (QA) procedure tracking the source throughout dose delivery
can detect dwell position and time errors in the multiple channels of the applicator.
A new MVC system with integrated real time in vivo treatment delivery QA has been developed
based on diodes embedded on the outer surface of the MVC. It has been pre-calibrated and
verified using a non-clinical treatment plan with consecutive test positions and dwell times within
each catheter, followed by the delivery of ten clinical plans of adjuvant vaginal cuff
brachytherapy following hysterectomy for endometrial cancer.
The non-clinical verification showed overall mean dwell position and time discrepancies between
the nominal and measured treatment of –0.2 ± 0.5 mm and -0.1 ± 0.1 s (k=1), respectively. The
clinical plans showed mean positional discrepancies of 0.2 ± 0.4 and 0.0 ± 0.8 mm, for the central
and peripheral catheters, respectively, and mean dwell time discrepancies of -0.1 ± 0.2 and -0.0 ±
0.1 s for central and peripheral catheters, respectively.
The innovative prototype of the MVC system has shown the ability to track the source with submm and sub-second accuracy, and demonstrated potential for its incorporation into the clinical
routine.
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1. Introduction
The multichannel vaginal cylinder (MVC) applicator has been widely adopted in gynecological
high dose rate (HDR) brachytherapy (BT) treatments. It has shown reductions in doses received
by organs-at-risk, as compared to the single channel vaginal cylinder (SVC) applicator, without
compromising the dose to the target. In fact, as compared to SVC the MVC geometry provides
more degrees of freedom (i.e., the source is also dwelling in peripheral channels) to optimize the
dose distribution for each patient [1-5].
The presence of multiple channels increases treatment complexity, and thus makes HDR
treatments more prone to error. Errors can arise as a result of transfer tube misconnections,
afterloader malfunction, and mistakes in afterloader calibration, among others, and thus affect
source stepping distances, dwell times, and dwell positions within the applicator. Moreover,
treatment errors often remain unknown due to a lack of real-time or post-treatment dose delivery
verification in the current treatment flow [6, 7].
Treatment verification is recommended in order to ensure optimal outcomes for the patient, and
can be done by measuring or visualizing the HDR source during dose delivery either as a quality
assurance (QA) procedure performed prior to treatment delivery, or for in vivo treatment QA.
Methods have been investigated with systems such as ion chamber [8] and two-dimensional (2D)
diode arrays [9], pixelated detectors [10], Gallium Nitride (GaN) probes [11], electronic portal
imaging devices (EPIDs) [12], plastic scintillators [13,14], diamond detectors [15], fluorescent
screen imaging [16], thermoluminescence dosimeters (TLDs) [17] and Alanine [18]. However, to
the best of our knowledge, among the listed methods only GaN-based dosimeters have been used
to perform in vivo QA of treatments delivered with MVCs. Alternative source tracking systems
that allow sub-millimeter and sub-second dwell position and dwell time verification in real-time
should therefore still be investigated.
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The aim of this study was to produce and assess an innovative prototype of a MVC applicator
with embedded and pre-calibrated diode detectors that can provide in vivo and real time QA of
the delivered treatment by comparing it to the prescribed plan.

2. Materials and Methods
2.1 MVC prototype description
The applicator prototype was designed and manufactured at the Centre for Medical Radiation
Physics (CMRP) at the University of Wollongong. It is 30 mm in diameter and contains seven
equally spaced peripheral channels and one central cavity to host the peripheral and central
catheters of the commercially available Vaginal CT/MR Multi Channel Applicator (Elekta
Brachytherapy, TH Veenendaal, NL), respectively. In particular, the peripheral catheters are
disposable plastic catheters with a diameter of 2 mm and an external length of 293 mm (i.e.,
“catheter with collar 6F”) and the central catheter is the reusable Intravaginal CT/MR Tube.
Epitaxial (epi) diode detectors were selected for HDR source tracking due to their high sensitivity
and radiation hardness, and embedded on the applicator surface. The diodes are fabricated on ptype epitaxial silicon with a sensitive volume of 1.5 x 1.5 x 0.5 mm3. They are connected to an inhouse developed reader based on the multichannel electrometer Application Specific Integrated
Circuit (ASIC) that is able to accommodate up to 32 detectors for simultaneous readout. Even
though the current integration of the diode is performed at an interval of 1 ms, the output signal
was averaged to 50 measurements to increase the signal to noise ratio, resulting in a final readout
frequency of 20 Hz. Accompanying readout software was also developed at the CMRP to display
the instantaneous and integral responses of the connected detectors in real-time. The raw output
signal of each detector is automatically stored for post-measurement analysis. A more detailed
description and characterization of the epi-diodes and data acquisition (DAQ) readout system is
provided elsewhere [9, 19].
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The applicator prototype was assembled by placing three diodes into dedicated grooves with an
angular interval of about 120 degrees around the surface of the MVC applicator at distances of
35, 37, and 39 mm from the applicator tip, respectively, ensuring a detection coverage of the
proximal 6-7 cm of the vagina. Since in adjuvant vaginal cuff BT following hysterectomy, as a
routine, it is recommended that the proximal 3-5 cm of the vagina be treated [20], the selected
diode arrangement would be appropriate to cover the clinically significant region. A phantom of
160 x 220 x 160 mm3 was fabricated using polymethylmethacrylate (PMMA) to surround the
applicator without any air gaps and ensure adequate scattering conditions. A picture of the
experimental setup used to perform all measurements of this study is shown in figure 1. The
MVC system is positioned inside the PMMA phantom with transfer tube connections in all
existing channels. The three diodes are connected to the DAQ system for readout, and read out in
real time throughout the irradiation outside the BT bunker.

2.2 Afterloader description
Measurements were performed using the Flexitron afterloading unit (Elekta Brachytherapy, TH
Veenendaal, NL) at the BT facility of the Fondazione IRCSS Istituto Nazionale dei Tumori (INT)
in Milan, Italy. The afterloader contains an Ir-192 source with a 3.5 mm active length
(Flexisource, Elekta) that is attached to a steel wire [21] and can be delivered using a total of 40
available treatment channels. The Air Kerma Strength SK of the source ranges between about 45
(when it is installed in the afterloader) and 20 mGy m2 h-1 (when it is removed and replaced). The
unit allows a minimal step size and dwell time of 1 mm and 0.1 seconds, respectively. The
positional accuracy of the system is ± 0.5 mm [22].

2.3 MVC system calibration
The first part of the study concerns the calibration of the MVC system - that is to assign to the
measured response of the diodes a source dwell time and position (with respect to a specific
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reference point) within the applicator catheters of the MVC system. The dwell position was
defined as the center of the active length of the source. The origin of the reference system was set
on the upper surface of the MVC applicator and the absolute location of the first dwell position in
each of the seven peripheral applicator channels was determined using GafChromic film
measurements. The film was wrapped around the applicator surface, aligning the edge with the tip
of the applicator, and the source was sent to the first dwell position (i.e., the most distal with
respect to the afterloader) for a dwell time of 3 seconds. Position locations exposed on the
GafChromic film were evaluated using a Matlab (The Mathworks, Natick, MA, USA) script to
determine the center of each Ir-192 exposure and its location with respect to the edge of the film.
Measurements were repeated three times, and the obtained average locations of the first dwell
position, given as the distance (mm) from the applicator surface, ± 0.1mm (k=1), were 7.1 mm,
6.9 mm, 6.8 mm, 7.1 mm, 6.9 mm, 6.5 mm and 6.5 mm, for the peripheral catheters 1 to 7,
respectively. The first dwell position in the central catheter was set as 5.5 mm and was taken from
the Elekta user manual.

2.3.1 MVC calibration for source dwell position detection
To calibrate the MVC system in terms of source position detection, the relationship between
diode response and source position was investigated. The source was sent to dwell positions of
1100-1288 mm in the peripheral channels and 1100-1300 mm in the central channel, respectively,
at a step size of 1 mm and a dwell time of 1 second in each position. 1288 mm and 1300 mm are
the first dwell positions (i.e., maximal distal positions) that can be set for the peripheral and
central catheters, respectively.
The output was normalized by SK at the time of measurement and averaged over all the readout
values corresponding to a near-constant diode response, and thus indicating a single programmed
dwell position (i.e., readouts corresponding to the source transiting from one dwell position to the
other when the response of the diode was monotonically variable were eliminated). The obtained
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mean responses R !"#!$ were plotted as a function of the source distance dcath from the applicator
tip, and those belonging to the two diodes with the higher signals were fitted with multi-term
Gaussian functions according to equation 1:
R !"#!$ (𝑑!"#! ) = a! ∙ e
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!!! !
( !"#!
)
!
!

+ a! ∙ e

!
!!! !
( !"#!
)
!
!

+⋯

Eq. 1

where an, bn and cn are the fitting parameters of the n-th term of the equation.
Thus, once the multi-term Gaussian functions are defined for the source dwelling in every
available catheter they can be used for finding the source dwelling position dcath in the given
catheter at any time. The multi-term Gaussian-interpolated diode response function (normalized
by the source SK) provides two possible solutions for the source dwell position. The ambiguity of
source position determination is avoided by taking into account the response of a second diode
located in a slightly different depth relative to the tip of the catheter in comparison to the diode
with highest response, as shown in figure 2.
A schematic of the applicator with the three diodes positioned on its surface is shown in figure 2.
An example of the diode response with the source dwelling in the central catheter is plotted as a
function of the source distance from the applicator tip. In this example, the diodes 1 and 3 were
selected as reference diodes for dwell position and time reconstruction.

2.3.2 MVC calibration for source dwell time detection
Source dwell time is determined from the plateaus in the diode signal i.e., the constancy of diode
response with respect to the time. Dwell time is calculated as the ratio of the number of
measurements in each plateau and the frequency of readout, set at 20 Hz throughout this study.
An example of a plot with clearly distinguishable consecutive dwelling position plateaus is given
in figure 3 for dwells of five second duration.

2.4 MVC system verification
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The system’s ability to reconstruct Ir-192 dwell positions and dwell times using the established
methodology was first verified using a test plan with multiple consecutive dwell positions in
every one of the eight applicator catheters. Chosen dwell positions with a step-size of 10 mm
covered a range of 60 mm and 70 mm (i.e., from 5.5 to 75.5 mm from the applicator tip) in the
peripheral and central channels, respectively, and were delivered for a dwell time of 5 seconds in
each position. The absolute differences Δp and Δt between nominal and measured dwell positions
and times, respectively, were then computed for every source position according to Δp = pmeas pnom and Δt = tmeas - tnom.
Following the first verification study, a total of ten BT treatments previously delivered at the
Fondazione IRCCS Istituto Nazionale dei Tumori to cervical cancer patients employing the 30mm MVC, were randomly selected from the database and delivered in-phantom. Overall, 181 and
106 dwell positions for the source dwelling in the central and in the lateral catheters, respectively,
were planned. Discrepancies between reconstructed and nominal dwell positions and times were
evaluated as described above.

3. Results
The quality of fitting parameters derived for the diode response functions used for dwell position
reconstruction in each catheter can be seen in table 1. The two diodes with the highest signal, the
number of Gaussian terms used for the interpolation curve, and their corresponding R2 values are
provided.
Following calibration of the MVC system, dwell position-time plots as those shown in figure 4
could be obtained for treatment delivery verification. An example of the source dwelling in the
central catheter during the delivery of the non-clinical plan (a), and of a complete clinical
treatment plan (i.e., central and the six peripheral channels C2 to C7) (b), are provided.
The distributions of all resulting dwell time and position discrepancies for the non-clinical plan
(i.e., step-size of 10 mm, dwell time 5 s in all available catheters) are given in figure 5, with the
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mean discrepancies for each single catheter reported in table 2. Overall mean dwell position and
time discrepancies were determined as –0.2 ± 0.5 mm and -0.1 ± 0.1 s (k=1), respectively. 50%
and 95% of absolute positional discrepancies were within 0.4 mm and 1.3 mm, respectively,
whereas 50% and 95% of absolute time discrepancies were within 0.1 s and 0.4 s, respectively.
Discrepancy distributions between nominal and reconstructed dwell positions and times for all 10
delivered clinical treatment plans are plotted in figure 5. The mean dwell position discrepancies
are 0.2 ± 0.4 mm and 0.0 ± 0.8 mm (k=1) for the central and lateral catheters, respectively. The
mean dwell time discrepancies are -0.1 ± 0.2 s and -0.0 ± 0.1 s (k=1) for the central and lateral
catheters, respectively.
In general, 50% and 95% of absolute positional discrepancies |Δp| were < 0.3 mm and < 0.8 mm
for the source dwelling in the central catheter, respectively, and < 0.5 mm and < 1.5 mm for the
source dwelling in the peripheral catheters, respectively. Overall, 96.2 and 77.9% of absolute
positional discrepancies were < 1 mm for the central and peripheral channels, respectively.
50% and 95% of absolute dwell time discrepancies |Δt| were < 0.05 s and < 0.40 s, respectively,
for the source dwelling in the central catheter, and < 0.05 s and < 0.20 s, respectively, for the
source dwelling in the peripheral catheters.
Figure 6 provides a graphical visualization of the correspondence between planned (i.e., nominal)
and measured dwell positions and times for the central and lateral catheters of the 10 delivered
clinical treatment plans. Higher discrepancies between planned and real dwell positions and times
are shown by the higher gaps between the red (nominal) and blue (measured) data points.

4. Discussion
In this study, an innovative prototype of a MVC applicator with embedded diode detectors was
produced. Preliminary measurements on a non-clinical and on 10 different clinical treatment
plans have demonstrated the MVC system’s ability to monitor the HDR source throughout the
entire dose delivery phase, providing in vivo and real time QA of the delivered treatment by

- 9-

comparing it to the prescribed plan. The system is in principle able to detect errors in dwell
position and dwell times, including spontaneous afterloader malfunction, incorrect applicator and
indexer lengths, mistakes in transfer tube connections, source calibration, and administration of
the incorrect treatment plan.
A great advantage is that the MVC system can be pre-calibrated via a relatively easy method, and
source positions and times can be obtained in real time without any assumptions or particular
dose distribution calculations within the applicator/patient. In fact, source positions are
constrained along the central and peripheral catheters, and the diodes have fixed positions with
respect to the catheters. Thus, for each possible source position in one of the eight treatment
channels, a unique solution exists from the combination of the two dosimeters with the highest
responses. This solution can be determined experimentally prior to the use of the applicator and is
valid without further recalibration in the case of stable diode response. Therefore, only a QA of
the diode stability with time is required. Moreover, specific corrections for the possible energy
and angular dependences of the diodes were not necessary, because the overall diode response
was taken as reference and intrinsically modeled with the multi-term Gaussian functions.
This is different to systems that are not built-in with the applicator, such as 2D arrays [8,9] or
EPIDs [12], where more complex assumptions, pre-calibrations and calculations have to be
performed to accurately reconstruct source positions inside the patient. For a correct calibration of
the MVC system, it is however very important that it is calibrated in the same conditions that are
present during treatment. Therefore, in order to ensure full-scattering conditions, a phantom was
fabricated to surround the applicator during calibration, without leaving any air gaps at the
applicator-phantom interface.
Another advantage of the proposed system over previously developed methods is that the diodes
used for Ir-192 tracking are incorporated directly over the dose delivery instrument, i.e., MVC
applicator, eliminating the introduction of any additional steps into the existing treatment
procedure for the radiation oncologist or the radiation therapy technologist. Prior to patient
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irradiation the diode detectors must simply be connected to the readout system. For full system
integration into the QA workflow, the readout system should ideally be connected with the
afterloader treatment console for a direct comparison between nominal (i.e., planned on the
console) and delivered (detected with the MVC system and calculated directly on the console)
dwell position and times.
The proposed pre-calibrated MVC system is the first prototype of the multichannel vaginal
cylindrical applicator with embedded diode detectors that can provide dwell positions and times
with generally sub-mm and sub-second accuracy in real time. To the best of our knowledge, it is
the first time ever that such a system is presented in literature. In fact, Wang et al [23] and Guiral
et al [24] also equipped a commercial MVC applicator with four GaN-based dosimeters. They
proposed a method for accurate in vivo determination of source dwell times and positions as a
QA of the delivered treatment plan. Despite the very promising error detectability shown and
evaluated in-phantom by means of testing intentionally introduced error protocols, a drawback of
the proposed system remains in the reduction of peripheral channels available for treatment. The
GaN-based dosimeters were hosted in four of the available treatment channels, thus significantly
limiting the dose distribution optimization potential of the MVC. Moreover, in Guiral et al, the
results mainly concern the use of the central catheter and only a simple test was performed on a
three channel instrumented applicator.
If comparing the results limited to the central catheter, mean dwell position and time
discrepancies are comparable. In particular, the discrepancies were -0.11 ± 0.7 mm and 0.2 ± 0.4
mm (k=1) for dwell positions in Guiral et al and in our study, respectively, and 0.05 ± 0.09 s and
-0.1 ± 0.2 s (k=1) for dwell times, respectively. In our study, it was additionally shown that
comparable accuracies can also be obtained for lateral catheters on 10 clinical treatments, with
resulting dwell position and time discrepancies of 0.0 ± 0.8 mm and -0.0 ± 0.1 s (k=1),
respectively.
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This study clearly shows feasibility of the method and a potential for future use of the MVC
system in the clinical routine. In principle, the diodes could be integrated to commercially
available MVC applicators of any diameter, establishing the MVC system with applicators that
are already clinically approved and familiar to operators. If these commercially available MVC
systems will be designed with dedicated grooves that accommodate individual diodes and exactly
fit the dimensions of the detectors, it will likely be possible that diodes could be removed and put
back after each sterilization cycle without the need of a new calibration. On the contrary,
recalibration will be necessary any time the diodes need to be replaced with new ones. Studies are
still ongoing to define the most convenient adjustment to properly integrate the diodes with
commercial applicators of different diameters
A range of source detection within the applicator of the proximal 60-70 mm of the vagina is
enough for the majority of clinical applications of adjuvant vaginal cuff BT after hysterectomy,
since the proximal 3-5 cm of the vagina are usually treated [20]. The current detection range
limitation is determined by a combination of diode sensitivity and their location over the
applicator. An increased number of diodes and their optimal distribution over the applicator could
in principle allow an extension of this range. Time and spatial resolutions are also in principle
good and would already allow the detection of significant delivery errors. A thorough evaluation
of the system’s ability to detect specific treatment errors will be conducted in the future.
Nevertheless, it must be noted that some improvements could still be accomplished to realize an
advanced version of the MVC system. In particular, since the diodes are particularly small and
since the reader is able to accommodate up to 32 detectors for simultaneous readout, additional
diodes could be added over the MVC surface. There could in principle be one diode at every
inter-channel space and some of them could also be placed closer to the applicator tip or to the
applicator end. In this case more than two diode responses could be used to mathematically
calculate the source position. Such an advanced diode assembly could possibly further improve
source detection accuracy, as for instance: i) in the tails of the current calibration curves, where
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diode signal is lower (e.g. close to the tip of the applicator); ii) in the peak of the current
calibration curves, where the source is dwelling directly above the sensitive volume of the diode
and it is not possible to distinguish two consecutive dwell positions because these provide a
similar response.
Even if, in the latter case, the second diode, located a few mm away, is able to accurately identify
the correct position between the two, an exception occurred in our study for source positions 35.5
and 38.5 mm in catheter 2, where both of the diodes were not able to distinguish the two
consecutive dwell positions, reconstructing both as 37.1 mm. By eliminating the current physical
restraint of the system, i.e., the presence of seven peripheral catheters and only three diodes,
resulting in catheter 2 having two diodes of a similar response, spatial uncertainties in close
proximity to the diode’s sensitive volume could possibly be decreased.
An intrinsic limitation of the developed method is that the source tracking system is incorporated
to the MVC applicator, but no conclusions can be drawn about the anatomical delivery of the
delivered dose distribution. The use of the system will therefore provide a valuable validation that
the delivered treatment is in accordance with the planned one, but no conclusions can be drawn
about the delivered dose distribution. In vivo dose measurements in the urethra or rectum
[5,6,11,13,17,18,25] will additionally be needed to provide a comprehensive evaluation of the
treatment. Further in vivo measurements are required to validate a possible combination of the
dosimetry and source tracking methods.

5. Conclusion
The innovative prototype of a pre-calibrated MVC applicator with embedded diodes has shown
the ability to track the HDR Ir-192 source during vaginal BT treatments with generally sub-mm
and sub-second accuracy. The system is able to provide online verification of source dwell
positions and times in real time for treatment verification, and there is potential for its future
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application in the clinical routine. Thorough studies to analyze the MVC system’s ability to detect
specific treatment errors and to investigate the possible combination of the MVC system with in
vivo dosimetry methods will be conducted in the future.
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Figure captions
Figure 1: (a) Cylindrical multichannel applicator with the peripheral catheters and three diodes
positioned around its surface (the central catheter is not shown in the image); (b) Two cylindrical
components of the MVC, with the possibility of using the intrauterine tube in the innermost piece
of the applicator, and the custom-made PMMA phantom to surround the applicator; (c)
experimental setup used for the study.

Figure 2: Multi-term Gaussian functions in the central catheter where the cross-sectional
horizontal view (a) of the applicator shows the Ir-192 source (red sphere) in the central channel,
and the three color-coded diodes positioned on the applicator surface. Corresponding diode
response curves are plotted as a function of the source distance from the applicator tip (b), and in
this case the diodes with the highest response i.e., diodes 1 and 3 are used for position and dwell
time reconstruction. The source in the dwell position is shown in the longitudinal view (c) with
diodes 1 and 3 fixed around the applicator perimeter.

Figure 3: Example of normalized diode response as seen during treatment time. Points between
the plateaus are due to the transit of the source from one dwell position to the next one.

Figure 4: Example of treatment delivery verification for a) catheter 1 of the test plan and for b) a
complete clinical treatment plan (i.e., central and the six peripheral channels C2 to C7). The
reconstructed and nominal dwell positions, shown in blue and red, respectively, are viewed as a
function of treatment time. Plot b shows that the treatment starts in the furthest position from the
applicator tip of the central catheter, delivering a total of 16 dwell positions of various dwell
times. At 222.3 seconds the central channel delivery is completed (marked by the red arrow). The
source then proceeds to two dwell positions 5 mm apart in peripheral channel 2 for 34.1 and 11.8
s in duration, respectively, and one dwell position in channel 3. The source then dwells in two
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positions in channel 4, 1 mm apart and lasting 33.7 s and 11.3 s, respectively, and then to one
dwell position in consecutive channels 5, 6, and 7 for dwell times of 33.0 s, 21.7 s, and 33.3 s,
respectively.

Figure 5: Discrepancy distributions between nominal and reconstructed dwell positions (a) and
times (c) for the non-clinical treatment, respectively, and for the 10 delivered clinical treatment
plans (i.e., (b) and (d), respectively). For the clinical treatment, distinct distributions for the
central and the peripheral catheters are shown. Histograms are fitted with Gaussian distributions,
which are also plotted with continuous lines.

Figure 6: Correspondence between the planned (red squares) and measured (blue dots) dwell
positions (a) and times (c) for the central catheter, respectively, and between planned and
measured dwell positions (b) and times (d) for the lateral catheters, respectively, in the 10
delivered clinical patient plans.
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Tables

Table 1. Calibration curve parameters for each catheter.
Catheter
C1
C2
C3
C4
C5
C6
C7
Central

Diodes
HIGH
D2
D2
D3
D3
D1
D1
D2
D1

LOW
D3
D3
D2
D1
D3
D2
D1
D3

No. of Gaussian terms
HIGH
LOW
4
3
4
3
4
2
4
2
4
2
3
2
4
2
3
3

- 20 -

R2 values
HIGH
1
1
1
1
>0.99
>0.99
1
1

LOW
>0.99
1
>0.99
>0.99
>0.99
>0.99
>0.99
1

Table 2: Results of the non-clinical dwell position and dwell time verification study with mean
absolute differences Δp and Δt between the nominal and measured dwell positions and times for
each catheter within the MVC, respectively.
Catheter Discrepancies
CATHETER

Δp (mm)

Δt (s)

C1

-0.2 ± 0.3

-0.2± 0.1

C2

0.0± 0.4

-0.2± 0.1

C3

-0.1± 0.4

-0.2± 0.1

C4

-0.5± 0.6

-0.1± 0.2

C5

-0.3± 0.5

-0.1± 0.0

C6

-0.1± 0.5

-0.2± 0.2

C7

-0.6± 0.5

-0.1± 0.1

Central

-0.1 ± 0.3

-0.1± 0.0
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